417 results on '"Nicholson, R. I."'
Search Results
2. erbB Signalling and Endocrine Sensitivity of Human Breast Cancer
3. Oestrogen-Deprivation in Breast Cancer: Clinical and Experimental Observations
4. Estrogen Receptors and Breast Cancer
5. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells
6. Growth factor signalling in endocrine and anti-growth factor resistant breast cancer
7. c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer
8. Control of microbial contamination of Franz diffusion cell receptor phase in the development of transcutaneous breast cancer therapeutics
9. Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer
10. Bidirectional cross talk between ERα and EGFR signalling pathways regulates tamoxifen-resistant growth
11. A dual immunocytochemical assay for oestrogen and epidermal growth factor receptors in tumour cell lines
12. Insulin-Like Growth Factor-I Receptor Signaling in Tamoxifen-Resistant Breast Cancer: A Supporting Role to the Epidermal Growth Factor Receptor
13. Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast
14. Molecular Mechanisms of Antiestrogen Action
15. Cellular effects of tamoxifen in primary breast cancer
16. The Antiepidermal Growth Factor Receptor Agent Gefitinib (ZD1839/Iressa) Improves Antihormone Response and Prevents Development of Resistance in Breast Cancer in Vitro
17. Neuroendocrine differentiation and prognosis in breast adenocarcinoma
18. Modulation of Epidermal Growth Factor Receptor in Endocrine-Resistant, Estrogen-Receptor-Positive Breast Cancer
19. Selection of primary breast cancer patients for adjuvant endocrine therapy - is oestrogen receptor alone adequate?
20. Quality control for the immunohistochemical demonstration of oestrogen and progesterone receptors
21. Novel antitumor peptide hormones with selective antitumor activity
22. Novel antitumor peptides and their mechanism of action
23. Steroid hormone receptors and their clinical significance in cancer
24. BCL2 expression in breast cancer: identification of patients who should not receive endocrine therapy
25. Oestrogen Receptors And Survival In Early Breast Cancer [With Reply]
26. Biological and clinical aspects of oestrogen receptor measurements in rapidly progressing breast cancer
27. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival
28. Expression of Ras P21, P53 and C-Erbb-2 in Advanced Breast-Cancer and Response to First Line Hormonal-Therapy
29. IGF-1R expression and activation in clinical breast cancer
30. Insulin-like growth factor-1 receptor signalling and acquired resistance to gefitinib (ZD1839; IRESSATM) in MCF-7 human breast cancer cells
31. Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells
32. Long-term effect of fulvestrant on signaling elements in breast cancer.
33. Dual targeting of Src and ER prevents acquired antihormone resistance in breast cancer cells
34. Consensus Statement
35. Deciphering antihormone-induced compensatory mechanisms in breast cancer and their therapeutic implications
36. Phosphorylation of ERα at serine 118 in primary breast cancer and in tamoxifen-resistant tumours is indicative of a complex role for ERα phosphorylation in breast cancer progression
37. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells
38. Growth factor pathway switching: implications for the use of gefitinib and trastuzumab
39. A randomised controlled trial of medroxyprogesterone acetate in mastalgia
40. Clinical Value of Epidermal Growth Factor Receptor Expression in Primary Breast Cancer
41. Polymer–drug conjugates: towards a novel approach for the treatment of endrocine-related cancer
42. Overview of tyrosine kinase inhibitors in clinical breast cancer
43. Growth factor signalling and resistance to selective oestrogen receptor modulators and pure anti-oestrogens: the use of anti-growth factor therapies to treat or delay endocrine resistance in breast cancer
44. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer
45. Development of strategies for the use of anti-growth factor treatments
46. Consensus Statement
47. Growth factor-driven mechanisms associated with resistance to estrogen deprivation in breast cancer: new opportunities for therapy
48. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells
49. Impact of altered growth factor signalling on endocrine response in breast cancer and the transition from ER+ to ER− disease
50. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.